Josep María Grinyó-rekin lankidetzan egindako argitalpenak (16)

2024

  1. Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients: Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration–dose ratio

    Nefrologia , Vol. 44, Núm. 2, pp. 204-216

2023

  1. A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction

    Kidney International, Vol. 104, Núm. 4, pp. 840-850

  2. CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach

    Pharmaceutics, Vol. 15, Núm. 12

  3. The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus Formulations

    Pharmaceutics, Vol. 15, Núm. 5

2022

  1. Dual Costimulatory and Coinhibitory Targeting with a Hybrid Fusion Protein as an Immunomodulatory Therapy in Lupus Nephritis Mice Models

    International journal of molecular sciences, Vol. 23, Núm. 15

  2. Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation

    Frontiers in Immunology, Vol. 13

2021

  1. Dual and opposite costimulatory targeting with a novel human fusion recombinant protein effectively prevents renal warm ischemia reperfusion injury and allograft rejection in murine models

    International Journal of Molecular Sciences, Vol. 22, Núm. 3, pp. 1-19

  2. Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation

    Frontiers in Pharmacology, Vol. 12

  3. Mycophenolic acid interferes the transcriptional regulation and protein trafficking of maturation surface markers in dendritic cells

    International Immunopharmacology, Vol. 91

  4. Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients

    Clinical Pharmacology and Therapeutics, Vol. 110, Núm. 1, pp. 238-247

  5. The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis

    Molecular Therapy - Nucleic Acids, Vol. 24, pp. 807-821

2020

  1. Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation

    Frontiers in Immunology, Vol. 11

  2. Validation and evaluation of four sample preparation methods for the quantification of intracellular tacrolimus in peripheral blood mononuclear cells by UHPLC-MS/MS

    Clinica Chimica Acta, Vol. 503, pp. 210-217

2019

  1. Measurement of calcineurin activity in peripheral blood mononuclear cells by ultra-high performance liquid chromatography-tandem mass spectrometry. Renal transplant recipients application (pharmacodynamic monitoring)

    Clinica Chimica Acta, Vol. 495, pp. 287-293

2018

  1. ANRIL as a genetic marker for cardiovascular events in renal transplant patients – an observational follow-up cohort study

    Transplant International, Vol. 31, Núm. 9, pp. 1018-1027

2016

  1. Online haemodiafiltration improves inflammatory state in dialysis patients: A longitudinal study

    PLoS ONE, Vol. 11, Núm. 10